News
SNBIF
9.40
NaN%
--
Citi Reaffirms Their Hold Rating on SanBio Co (SNBIF)
TipRanks · 04/17 10:05
Morgan Stanley Sticks to Their Hold Rating for SanBio Co (SNBIF)
TipRanks · 04/02 10:17
SanBio Outlines FY2026 Results and Global Regenerative Medicine Ambitions
TipRanks · 03/25 07:03
Analysts Have Conflicting Sentiments on These Healthcare Companies: SanBio Co (OtherSNBIF) and Trevi Therapeutics (TRVI)
TipRanks · 03/18 10:10
SanBio to Restructure Capital to Eliminate Deficit and Boost Financial Flexibility
TipRanks · 03/17 07:01
SanBio Books Foreign Exchange Losses and Financing Costs in FY2026 Results
TipRanks · 03/17 07:01
SanBio Deepens Losses but Fortifies Balance Sheet as It Awaits AKUUGO Revenue
TipRanks · 03/17 07:01
SanBio Finalizes Employee Stock Option Terms for 75,000 Shares
TipRanks · 01/27 07:52
SanBio Issues New Employee Stock Options to Support Long-Term Growth
TipRanks · 01/09 07:01
SanBio Co. Records Significant Non-Operating Expenses and Deferred Income Taxes
TipRanks · 12/15/2025 07:01
SanBio Reports Continued Financial Losses Amid Operational Challenges
TipRanks · 12/15/2025 07:01
SanBio initiated with a Neutral at UBS
TipRanks · 12/14/2025 14:10
UBS Initiates a Hold Rating on SanBio Co (SNBIF)
TipRanks · 12/14/2025 13:55
SanBio Gains Approval for AKUUGO Marketing Changes
TipRanks · 12/09/2025 06:54
SanBio Co. Announces International Offering to Fund Key Clinical Trials
TipRanks · 11/06/2025 14:52
SanBio Co. Announces International Share Offering to Fund Regenerative Medicine Expansion
TipRanks · 11/06/2025 08:27
SanBio’s AKUUGO Gains Approval for Launch, Eyes Global Expansion
TipRanks · 10/16/2025 11:52
SanBio Co. Reports Losses Amid R&D Investments
Barchart · 10/04/2025 22:54
SanBio Awaits Regulatory Decision on AKUUGO Suspension
TipRanks · 10/02/2025 06:52
More
Webull provides a variety of real-time SNBIF stock news. You can receive the latest news about Sanbio Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About SNBIF
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).